Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 10, Issue 11, Pages 868-880Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd3531
Keywords
-
Funding
- Canton of Basel
- Louis-Jeantet Foundation
- Swiss National Science Foundation
Ask authors/readers for more resources
Mammalian target of rapamycin (mTOR) is an atypical protein kinase that controls growth and metabolism in response to nutrients, growth factors and cellular energy levels, and it is frequently dysregulated in cancer and metabolic disorders. Rapamycin is an allosteric inhibitor of mTOR, and was approved as an immunosuppressant in 1999. In recent years, interest has focused on its potential as an anticancer drug. However, the performance of rapamycin and its analogues (rapalogues) has been undistinguished despite isolated successes in subsets of cancer, suggesting that the full therapeutic potential of targeting mTOR has yet to be exploited. A new generation of ATP-competitive inhibitors that directly target the mTOR catalytic site display potent and comprehensive mTOR inhibition and are in early clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available